Core Viewpoint - The announcement highlights that Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., has received approval for a Phase III clinical trial of the innovative drug Anladiwei granules for treating influenza A in children aged 2 to 11 [1] Group 1 - Zhongsheng Pharmaceutical's subsidiary has received ethical approval from the Capital Medical University Affiliated Beijing Children's Hospital for a clinical research project [1] - The clinical trial will focus on the safety and efficacy of Anladiwei granules in children with uncomplicated influenza A [1] - Anladiwei tablets (brand name: Anruiwei) are the world's first targeted innovative drug for influenza A, designed to inhibit the PB2 subunit of the influenza A virus RNA polymerase [1] Group 2 - Anladiwei is characterized by its rapid action, strong efficacy, and low resistance [1] - The drug was approved for market launch by the National Medical Products Administration in May 2025 [1]

Core Viewpoint - The announcement from Zhongsheng Pharmaceutical (002317.SZ) indicates that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received approval for a Phase III clinical trial of the innovative drug Anladiwei granules for treating uncomplicated influenza A in children aged 2 to 11 years [1] Group 1 - The clinical trial is a multicenter, randomized, double-blind, positive-controlled study focusing on the safety and efficacy of Anladiwei granules [1] - Anladiwei tablets (brand name: Anruiwei®) are the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, designed for the treatment of uncomplicated influenza A in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, and it was approved for market launch by the National Medical Products Administration in May 2025 [1]

Core Viewpoint - Zhongsheng Pharmaceutical (002317.SZ) announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., received approval from the Medical Ethics Committee of Beijing Children's Hospital for a clinical research project to conduct a Phase III clinical trial of the innovative drug Anladiwei granules for the treatment of uncomplicated influenza A in children aged 2 to 11 years [1] Group 1 - The clinical trial is a multicenter, randomized, double-blind, positive-controlled study [1] - Anladiwei tablets (brand name: Anruiwei) are the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus [1] - The drug is designed for the treatment of uncomplicated influenza A in adults and is characterized by rapid action, strong efficacy, and low resistance [1] Group 2 - Anladiwei was approved for market launch by the National Medical Products Administration in May 2025 [1]

众生药业公告称，公司控股子公司众生睿创收到北京儿童医院伦理批件，同意昂拉地韦颗粒在2~11岁 儿童单纯性甲型流感患者中开展III期临床试验。 ...

证券代码：002317 公告编号：2025-100 广东众生药业股份有限公司 关于控股子公司获得一类创新药 昂拉地韦颗粒 III 期临床试验伦理批件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众 生睿创生物科技有限公司（以下简称"众生睿创"）收到组长单位首都医科大学 附属北京儿童医院医学伦理委员会临床研究项目审查批件，同意一类创新药物昂 拉地韦颗粒在 2~11 岁儿童单纯性甲型流感参与者安全性、有效性的多中心、随 机、双盲、阳性对照 III 期临床试验开展。具体情况如下： 一、昂拉地韦临床试验进展情况 昂拉地韦片（商品名：安睿威®）是全球首款靶向甲型流感病毒 RNA 聚合 酶 PB2 亚基的一类创新药，适用于成人单纯性甲型流感患者的治疗，具有快速、 强效、低耐药等特点，于 2025 年 5 月获国家药监局批准上市。 昂拉地韦颗粒是公司为方便儿童及吞咽困难的流感患者用药，开发的用于治 疗甲型流感的一类创新药物。昂拉地韦颗粒的 II 期临床试验结果表现出积极的 疗效和良好的安全性，试验结果 ...

（文章来源：证券日报） 证券日报网讯众生药业9月29日在互动平台回答投资者提问时表示，公司三季度业绩请留意公司公告。 ...

证券日报网讯众生药业（002317）9月29日在互动平台回答投资者提问时表示，公司的股价受行业周 期、市场情绪、宏观政策环境等多重因素的影响。在严格遵守证券法等相关规定的前提下，公司将继续 以提高经营质量为基础，持续完善公司治理，适当时依法合规综合运用资本市场工具和运作方式，拓展 业务规模，逐步提高经营业绩，加强与投资者沟通，持续为股东创造更大价值。 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Viewpoints - The acquisition of Metsera by Pfizer, valued at approximately $4.9 billion, underscores the significant potential and long-term growth prospects of the weight loss drug market, particularly in the GLP-1 segment [2][24]. - The report emphasizes the urgent demand for next-generation therapies, such as oral formulations and multi-target drugs, indicating a competitive landscape in the global GLP-1 research race [2][24]. - The Chinese weight loss drug industry is poised for growth, with a focus on companies that demonstrate strong sales execution and advanced research capabilities [3][24]. Summary by Sections Market Review - The pharmaceutical and biotechnology index fell by 2.20%, underperforming the CSI 300 index by 3.27 percentage points, ranking 24th among 31 sub-industries [1][16]. Key Company Insights - Companies to watch include Innovent Biologics (H), Heng Rui Medicine, Borui Medicine, Zhongsheng Pharmaceutical, Nawei Technology, WuXi AppTec (A+H), and Kelaiying (A+H) as they are expected to benefit from the expanding GLP-1 industry chain [3][24]. Annual Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [25]. - Key areas of interest include hospital policy support for innovative drugs and devices, expanding public demand for blood products, home medical devices, and the weight loss drug industry chain [25]. Company Earnings Forecast and Valuation - The report provides earnings per share (EPS) and price-to-earnings (PE) ratios for key companies, indicating a "Buy" rating for WuXi AppTec and Innovent Biologics, and an "Overweight" rating for Heng Rui Medicine [4]. Market Trends - The global weight loss drug market is experiencing rapid growth, with Pfizer's acquisition of Metsera highlighting the increasing market space associated with obesity-related health issues [28]. - The report notes that the commercialization of domestic weight loss drugs will hinge on sales capabilities and research advancements [3][24]. Important Company Announcements - Recent announcements include clinical trial updates and new drug applications from various companies, indicating ongoing innovation and development within the sector [27]. Financial Data - The basic medical insurance income for the first seven months of 2025 reached 1,684.7 billion yuan, with expenditures amounting to 1,369.7 billion yuan, reflecting the financial landscape impacting the pharmaceutical industry [30]. Price Trends - The report notes a decline in antibiotic prices and stability in cardiovascular raw material drug prices, which may influence the cost structure for pharmaceutical companies [36][43]. Conclusion - The report presents a positive outlook for the pharmaceutical and biotechnology sector, particularly in the weight loss drug market, driven by significant acquisitions and a growing demand for innovative therapies [2][24].

每经AI快讯，有投资者在投资者互动平台提问：贵公司的三靶点减肥药的优势在哪？ 众生药业（002317.SZ）9月29日在投资者互动平台表示，公司RAY0221是超长效的GLP-1/GIP/GCG三受 体激动剂，具有良好的药代特性，有望在临床中实现每两周及以上注射一次的用药潜力。 （记者 胡玲） ...

证券日报网讯 众生药业9月26日在互动平台回答投资者提问时表示，公司始终坚持合规经营，规范披 露，严格依据信息披露规则履行信息披露责任，不存在应披露而未披露事项。公司三季度业绩请留意公 司公告。 （编辑 袁冠琳） ...